Clio Asset Management LLC cut its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 2.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 24,294 shares of the conglomerate’s stock after selling 589 shares during the quarter. Danaher accounts for 4.1% of Clio Asset Management LLC’s investment portfolio, making the stock its 11th biggest position. Clio Asset Management LLC’s holdings in Danaher were worth $5,577,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Fort Pitt Capital Group LLC raised its position in Danaher by 3.2% during the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock worth $66,194,000 after acquiring an additional 7,421 shares in the last quarter. Good Life Advisors LLC bought a new stake in shares of Danaher in the 3rd quarter valued at about $217,000. ORG Partners LLC grew its holdings in Danaher by 1,212.8% during the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after purchasing an additional 2,559 shares during the period. Harvest Portfolios Group Inc. increased its position in Danaher by 1.2% during the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after buying an additional 2,465 shares during the last quarter. Finally, Stifel Financial Corp raised its stake in Danaher by 1.3% in the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after buying an additional 11,216 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.
Analyst Ratings Changes
A number of research analysts recently weighed in on DHR shares. Robert W. Baird decreased their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Royal Bank of Canada decreased their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Raymond James cut their target price on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. TD Cowen upped their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Finally, Stephens restated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $285.55.
Danaher Price Performance
DHR stock opened at $245.95 on Monday. The company’s 50-day moving average price is $235.33 and its two-hundred day moving average price is $253.62. The firm has a market cap of $177.65 billion, a P/E ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70.
Danaher Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is 20.61%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- Top Biotech Stocks: Exploring Innovation Opportunities
- D-Wave: Recent Updates Propel Shares Off 2025 Lows
- What Are the U.K. Market Holidays? How to Invest and Trade
- Health-Tech Revival: 3 Stocks Set for a Big 2025 Rebound
- What is the NASDAQ Stock Exchange?
- How the $500 Billion Stargate Investment Can Boost These Stocks
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.